Share price · INCY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
See what was announced around each unusual move
Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.
Assets
(10 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | CSF-1RMonoclonal antibody | Graft-versus-Host Disease Chronic Graft-versus-Host Disease | |
Pemigatinib(Pemazyre) | Approved | FGFR1/2/3Small molecule | Non-Small Cell Lung CancerBiliary Tract Cancer Cholangiocarcinoma |
Ponatinib(ICLUSIG) | Approved | —Small molecule | Chronic Myeloid Leukemia |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerMerkel Cell CarcinomaAnal Cancer Squamous Cell Carcinoma of the Anal Canal | |
| Approved | JAK1/2Small molecule | Atopic DermatitisMyelofibrosisPolycythemia VeraGraft-versus-Host DiseaseVitiligo | |
| Approved | Undisclosed / early pipelineMonoclonal antibody | Diffuse Large B-Cell LymphomaFollicular Lymphoma | |
| Phase 3 | —Monoclonal antibody | Essential Thrombocythemia | |
| Phase 3 | TGF-βR2 and PD-1 (conditional bispecific)Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | —Small molecule | Ovarian Cancer | |
| Phase 3 | KRAS G12DSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.